Haemato AG
XETRA:HAEK

Watchlist Manager
Haemato AG Logo
Haemato AG
XETRA:HAEK
Watchlist
Price: 21.4 EUR -1.83% Market Closed
Market Cap: €111.5m

Haemato AG
Investor Relations

Haemato AG engages in the pharmaceutical industry. The company is headquartered in Schoenefeld, Brandenburg. The company went IPO on 2012-03-26. The firm trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The firm's main markets are Europe, North America and Japan. The company also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The firm's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Attila Strauss
MD & Member of Management Board
No Bio Available

Contacts

Address
BRANDENBURG
Schoenefeld
Lilienthalstrasse 5c
Contacts
+4930897308670.0
haemato.ag
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett